Case 17-2008: A 63-year-old man with metastatic renal-cell carcinoma

New England Journal of Medicine

Volumn 358, Issue 22, 2008, Pages 2389-2396

  Michaelson, M Dror ^a,c   Iliopoulos, Othon ^a,c   McDermott, David F ^b,c   McGovern, Francis J ^a,c   Harisinghani, Mukesh G ^a,c   Oliva, Esther ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISPAGULA; LISINOPRIL; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; KIDNEY CARCINOMA; LABORATORY TEST; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIOGRAPHY; SCROTUM; VARICOCELE; ADRENAL TUMOR; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; FATALITY; KIDNEY TUMOR; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATHOLOGY; PROGNOSIS;

ADRENAL GLAND NEOPLASMS; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; PYRROLES;

EID: 44349170138     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0802449     Document Type: Article

References (51)

1. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
2. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
3. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. 2. Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005;185:72-80.
4. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. 1. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005;185:64-71.
5. Schwartz BF, Rewcastle JC, Powell T, Whelan C, Manny T Jr, Vestal JC. Cryoablation of small peripheral renal masses: a retrospective analysis. Urology 2006;68:Suppl:14-8.
6. Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int 2007;99:1265-70.
7. Shuch BM, Lam JS, Belldegrun AS, Figlin RA. Prognostic factors in renal cell carcinoma. Semin Oncol 2006;33:563-75.
8. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76:2543-9.
9. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
10. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-91.
11. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001;25:275-84.
12. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604-14.
13. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005;6:7-18.
14. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
15. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-62.
16. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-64.
17. Jemal A, Seigel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
18. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
19. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1265-71.
20. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148:1247-8.
21. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003;21:884-90.
22. Lesimple T, Moisan A, Guillé F, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 2000;23:675-9.
23. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
24. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425.
25. Négrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000;18:4009-15.
26. Medical Research Council Renal Cancer Collaborators. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
27. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
28. Yang JC, Sherry RM, Stienberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
29. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41. [Erratum, J Clin Oncol 2005;23:2877.]
30. Belldegrun A, Webb DE, Austin HA III, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989;141:499-503.
31. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98.
32. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005;23:Suppl:380s. abstract.
33. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75.
34. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002;13:1460-8.
35. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005;28:488-95.
36. Bui MHT, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
37. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
38. Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:Suppl:386s. abstract.
39. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
40. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
41. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-6295S.
42. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
43. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80.
44. Ivan M, Kondo K, Yang H, et al. HIF1alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for oxygen sensing. Science 2001;292:464-8.
45. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 2006;24:5593-600.
46. Yang JC, Haworth L, Sherry RM, et al. A Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
47. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6.
48. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
49. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
50. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. [Erratum, N Engl J Med 2007;357:203.]
51. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.